Lupus & antiphospholipid syndrome
Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021
Authors' conclusion
Certain chronic comorbidities and SLE medications increase the odds of progression to severe COVID-19 among patients with SLE, but vaccination confers significant protection.
Study context
- Population
- Adults with systemic lupus erythematosus (SLE) and a COVID-19 diagnosis between 1 April 2020 and 31 December 2021, Merative MarketScan Databases (US)
- Participants
- 2,890 adults
- Outcome
- Severe COVID-19 (hospitalisation with a COVID-19 diagnosis)
Methodological detailsadministrative claims database, backward stepwise logistic regression
- Administrative claims database
- Backward stepwise logistic regression
Main finding
As reported in the abstract
Odds of progression to severe COVID-19
Odds ratio (95% CI)
Rituximab
2.92(1.67–5.12)
Renal failure
2.15(1.56–2.97)
Medicaidvs Commercial
2.01(1.58–2.57)
Complicated hypertension
1.96(1.38–2.77)
Vaccination
0.68(0.54–0.87)
Observational data: associations, not effects.
Original publication
Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021. RMD Open. Published 17 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →